<DOC>
	<DOC>NCT01641120</DOC>
	<brief_summary>The purpose of this study is to evaluate patients' views when injecting Avonex intramuscularly.</brief_summary>
	<brief_title>Assessing Tolerability of Avonex Intramuscular Injections</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Between 18 65 years of age; Confirmed diagnosis of Relapsing Remitting Multiple Sclerosis; Currently being treated with Avonex速 for at least 90 days; Using 25 gauge needles for injection of Avonex速 for at least 90 days; Willing and able to complete study questionnaires; and Provided informed consent to participate in this study Diagnosis of Progressive Multiple Sclerosis; History of recent illness or infection; History of allergic reaction to Avonex速; Any prior usage of a 30 gauge needle for administration of Avonex速; Concurrent treatment with other immunomodulating therapies; Pregnant or planning on becoming pregnant; Nursing mothers; and Unable to complete the requirements of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Intramuscular Injections</keyword>
	<keyword>Relapsing Remitting</keyword>
</DOC>